Related Experiment Videos
Atorvastatin improves endothelial function in renal-transplant recipients
A Asberg1, A Hartmann, E Fjeldså
1Laboratory for Renal Physiology, Section of Nephrology, Medical Department, The National Hospital, N-0027 Oslo, Norway.
Summary
Atorvastatin significantly reduced cholesterol and improved endothelial function in kidney transplant patients. This suggests a potential protective effect via the endothelial-nitric oxide pathway.
Area of Science:
- Cardiology
- Nephrology
- Pharmacology
Background:
- Hyperlipidemia and endothelial dysfunction are common in cyclosporin A (CsA)-treated renal transplant recipients.
- These conditions increase the risk of atherosclerosis and cardiovascular mortality.
- Statins may improve endothelial function beyond cholesterol reduction.
Purpose of the Study:
- To assess the effects of atorvastatin on serum lipids and endothelial function.
- To evaluate atorvastatin's impact in CsA-treated renal transplant recipients.
Main Methods:
- Pilot study involving 22 renal transplant recipients on CsA and prednisolone.
- 4-week open trial of 10 mg/day atorvastatin.
- Assessment of forearm skin microvasculature endothelial function using acetylcholine and laser Doppler flowmetry.
- Measurement of serum lipids, endothelin-1 (ET-1), nitric oxide (NO), and von Willebrand factor (vWF).
Main Results:
- Significant reductions in total cholesterol (26.8%) and LDL cholesterol (41.5%) after 4 weeks.
- Significant improvement in endothelial function (AUC(ACh): 538 to 682 AU x min, P=0.042).
- Borderline significant increase in plasma NO levels (49 to 57 micromol/l, P=0.051).
- No significant changes in plasma ET-1 or vWF levels.
Conclusions:
- Atorvastatin effectively lowers cholesterol and improves endothelial function in renal transplant recipients.
- Increased NO levels suggest a potential endothelial protective effect through the NO pathway.
- Atorvastatin may offer cardiovascular benefits in this patient population.